Page 2 | Medtech — Trading Ideas on TradingView

NAVAMEDIC (NAVA) | Perfect Technically but Fundamentally So-So!Hi, Navamedic ASA, a MedTech and pharmaceutical company, in-licenses, buys and markets pharmaceuticals and other health care products in the Northern European region. Considering technical viewpoints then Navamedic has started to approach a pretty strong support area, a lot of criteria make up a strong crossing area. To be honest, I don't know much about Navamedic fundamentals but I can say, if you see some perspective in the future then this would be your perfect spot to buy it if you don't see then SKIP IT!! Technically a strong support area/buy-zone consists of: 1) A very strong resistance level becomes support. The price tried to break above the lower orange line 9(!) years and in the last year, it finally was successful. Now, this very strong resistance should act as a support level. 2) Inside the green buy-zone are also Monthly EMA50 and EMA100, plus Weekly EMA200 - all of them should act as support levels. 3) Fibonacci Golden ratio - Fibo retracement 62% 4) Navamedic becomes a member of a 50% club if the price reaches into the marked area. 5) Weekly timeframe AB=CD 6) Weekly timeframe channel projection It should be a pretty good spot to gain short-term profits, a perfect area should stay between 11.00-12.50 As said, do your own fundamental research and if this matching with my technical analysis viewpoints then you are ready to go! If it doesn't match then...skip it!! Regards, Vaido

Coloplast: Watch for break of black resistance line at 818 DKK Coloplast is in a solid uptrend that goes years back. However, this resistance needs to be crossed in order for it to go higher. One could then wait for a small retracement to the black line that then needs to hold as support for it to bounce further up to 900 DKK

Gartley + Additional data release today Friday, October 11, 2019 ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. NEXT EARNING: Nov 11, 2019 MARKET CAP: $333.254 Million Technical Analysis: -Bullish Gartley pattern -Fibonacci 876 retracement is an important reversal level in high volatility trades. -Our MS Signal oscillator indicating RSI moving higher and now being a potential good time to buy for a bounce. -MS CCI Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming) Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watchlist!! Thanks in advance. Disclosure: I am long ADVM. I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.

The Conformis Come-Back Conformis Inc. (Nasdaq: CFMS) is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture & sell patient specific joint replacement implants. The implants are designed to fit each patient's unique anatomy. CFMS stated in their previous ER (July 31, 2019), the company was updating their 2019 outlook to have "generally flat year-over-year product revenue growth for the full year 2019." The 'expected decrease in growth' was primarily due to denials in coverage from Aetna, the 3rd largest commercial payer. During the conference call, CFMS said they had "submitted its clinical and economic data to Aetna and understands that Aetna is currently reviewing its medical coverage policy." During the conference call, Conformis CEO suggested a potential update was coming this September from Aetna. As we approach mid-month, price has held 50 retracement from the lower-high made on August 28, 2019 ($2.33 ). Conformis stated that the letter denying coverage from Aetna only referred to Conformis as a company, rather than a product denial per usual standards. If Aetna did make a mistake and is willing to cover the Conformis custom joint replacements, this could bring massive upside to the current stock price.I am forecasting a $5 PT (assuming CFMS gets Aetna coverage as they did with Cigna before). Data from July 2019 10-K Market Cap: $137.357 Million Cash : $20.66 Million Revenue (product and royalty): $19.593 Million YoY Rev: +3% 52 Week High: $4.83 Ave Vol(10 Day): 628,900 Shares Outstanding: 68.68 Million Shares Float: 50.01 Million Technical's As shown in the previous chart , CFMS is positioned for a breakout. Price has continued to hold the 50% retracement from the Aug. 28, 2019 high. Previous patterns from January 2019 show similar price movement (trend-line in blue), indicating a "new" uptrend in the making. -Bullish Gartley in tact; -Aligning Fib time-cycles; -RSI approaching breakout level; -Our proprietary indicator showing strong momentum going into tomorrow's trading session (Flips green = Bullish AF), Weekly flashing bullish signal. Conclusion Potential of medicare approval for total knee replacement at surgery centers in 2020 is a huge opportunity as baby boomer population grows. The Aetna reimbursement issue will pass (as Cigna did). The soon to be released total hip system is being undervalued by the market. I am forecasting a $5 PT foregoing CFMS getting Aetna coverage. To read more of my analysis on CFMS visit our site, here . Please like and follow so I can continue finding awesome charts! Thanks in advance team d+) Disclosure: I am long CFMS. This is not a note to buy or sell. Please do your homework before investing.

Bullish Gartley About CFMS Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy. Technicals Bullish Gartley pattern (786 retracement) Fibonacci confluence at the 1.272 extension 382 continuation pattern (Keeps bouncing off and making higher lows-- if it continues it could be used to further add) In-line with Fibonacci time-cycles RSI pushing higher on Daily and Weekly Potential gap up to fill up to the $2.75 level. Conclusion : CFMS has sufficient funds, great management and recently received some 510 certifications while broader markets were selling off. Looking to re-claim those prior gains. Will revisit the trade at or around time of the gap filling. Like and follow so I can continue finding awesome charts and trades. Thank you in advance d+) Twitter + Instagram @VolatilityWatch Disclosure: I am long CFMS. This is not a note to buy or sell, please do your homework before investing.

Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and instagram @ #VolatilityWatch Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.

Photocure stock in correction after Q4 2018 report - time to buy As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price. At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time to move in for new investors.